Cargando…
Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections
Introduced in the late 1950s, polyenes represent the oldest family of antifungal drugs. The discovery of amphotericin B and its therapeutic uses is considered one of the most important scientific milestones of the twentieth century . Despite its toxic potential, it remains useful in the treatment of...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954977/ https://www.ncbi.nlm.nih.gov/pubmed/33523419 http://dx.doi.org/10.1007/s40121-020-00382-7 |
_version_ | 1783664171083104256 |
---|---|
author | Cavassin, Francelise B. Baú-Carneiro, João Luiz Vilas-Boas, Rogério R. Queiroz-Telles, Flávio |
author_facet | Cavassin, Francelise B. Baú-Carneiro, João Luiz Vilas-Boas, Rogério R. Queiroz-Telles, Flávio |
author_sort | Cavassin, Francelise B. |
collection | PubMed |
description | Introduced in the late 1950s, polyenes represent the oldest family of antifungal drugs. The discovery of amphotericin B and its therapeutic uses is considered one of the most important scientific milestones of the twentieth century . Despite its toxic potential, it remains useful in the treatment of invasive fungal diseases owing to its broad spectrum of activity, low resistance rate, and excellent clinical and pharmacological action. The well-reported and defined toxicity of the conventional drug has meant that much attention has been paid to the development of new products that could minimize this effect. As a result, lipid-based formulations of amphotericin B have emerged and, even keeping the active principle in common, present distinct characteristics that may influence therapeutic results. This study presents an overview of the pharmacological properties of the different formulations for systemic use of amphotericin B available for the treatment of invasive fungal infections, highlighting the characteristics related to their chemical, pharmacokinetic structures, drug–target interactions, stability, and others, and points out the most relevant aspects for clinical practice. |
format | Online Article Text |
id | pubmed-7954977 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-79549772021-03-28 Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections Cavassin, Francelise B. Baú-Carneiro, João Luiz Vilas-Boas, Rogério R. Queiroz-Telles, Flávio Infect Dis Ther Review Introduced in the late 1950s, polyenes represent the oldest family of antifungal drugs. The discovery of amphotericin B and its therapeutic uses is considered one of the most important scientific milestones of the twentieth century . Despite its toxic potential, it remains useful in the treatment of invasive fungal diseases owing to its broad spectrum of activity, low resistance rate, and excellent clinical and pharmacological action. The well-reported and defined toxicity of the conventional drug has meant that much attention has been paid to the development of new products that could minimize this effect. As a result, lipid-based formulations of amphotericin B have emerged and, even keeping the active principle in common, present distinct characteristics that may influence therapeutic results. This study presents an overview of the pharmacological properties of the different formulations for systemic use of amphotericin B available for the treatment of invasive fungal infections, highlighting the characteristics related to their chemical, pharmacokinetic structures, drug–target interactions, stability, and others, and points out the most relevant aspects for clinical practice. Springer Healthcare 2021-02-01 2021-03 /pmc/articles/PMC7954977/ /pubmed/33523419 http://dx.doi.org/10.1007/s40121-020-00382-7 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Review Cavassin, Francelise B. Baú-Carneiro, João Luiz Vilas-Boas, Rogério R. Queiroz-Telles, Flávio Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections |
title | Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections |
title_full | Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections |
title_fullStr | Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections |
title_full_unstemmed | Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections |
title_short | Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections |
title_sort | sixty years of amphotericin b: an overview of the main antifungal agent used to treat invasive fungal infections |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954977/ https://www.ncbi.nlm.nih.gov/pubmed/33523419 http://dx.doi.org/10.1007/s40121-020-00382-7 |
work_keys_str_mv | AT cavassinfranceliseb sixtyyearsofamphotericinbanoverviewofthemainantifungalagentusedtotreatinvasivefungalinfections AT baucarneirojoaoluiz sixtyyearsofamphotericinbanoverviewofthemainantifungalagentusedtotreatinvasivefungalinfections AT vilasboasrogerior sixtyyearsofamphotericinbanoverviewofthemainantifungalagentusedtotreatinvasivefungalinfections AT queiroztellesflavio sixtyyearsofamphotericinbanoverviewofthemainantifungalagentusedtotreatinvasivefungalinfections |